There has been ongoing controversy regarding the clinical meaningfulness of PPI’s attenuation of the anti-platelet effect of clopidogrel. In this large retrospective cohort of over 20,000 patients discharged on clopidogrel (from a state-wide medicaid database), researchers found those also discharged on a PPI had a 50% reduced risk of re-hospitalization with GI bleed, but no significantly increased risk of a cardiovascular event. This study and others suggest that PPI’s and clopidogrel can be used concomitantly, but avoiding unnecessary PPI’s in patients at high risk for cardiovascular events is still prudent (abstract). In addition, pantoprazole is probably a better choice than omeprazole, if a PPI is required (abstract)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment